Publications

BibTex format

@article{Reyes:2022:10.1186/s13054-022-04155-1,
author = {Reyes, LF and Murthy, S and Garcia-Gallo, E and Merson, L and Ibanez-Prada, ED and Rello, J and Fuentes, Y and Martin-Loeches, I and Bozza, F and Duque, S and Taccone, FS and Fowler, RA and Kartsonaki, C and Goncalves, BP and Citarella, BW and Aryal, D and Burhan, E and Cummings, MJ and Delmas, C and Diaz, R and Figueiredo-Mello, C and Hashmi, M and Panda, PK and Jimenez, MP and Rincon, DFB and Thomson, D and Nichol, A and Marshall, JC and Olliaro, PL},
doi = {10.1186/s13054-022-04155-1},
journal = {Critical Care (UK)},
pages = {1--16},
title = {Respiratory support in patients with severe COVID-19 in the International Severe Acute Respiratory and Emerging Infection (ISARIC) COVID-19 study: a prospective, multinational, observational study},
url = {http://dx.doi.org/10.1186/s13054-022-04155-1},
volume = {26},
year = {2022}
}

Download

RIS format (EndNote, RefMan)

TY  - JOUR
AB  - BackgroundUp to 30% of hospitalised patients with COVID-19 require advanced respiratory support, including high-flow nasal cannulas (HFNC), non-invasive mechanical ventilation (NIV), or invasive mechanical ventilation (IMV). We aimed to describe the clinical characteristics, outcomes and risk factors for failing non-invasive respiratory support in patients treated with severe COVID-19 during the first two years of the pandemic in high-income countries (HICs) and low middle-income countries (LMICs).MethodsThis is a multinational, multicentre, prospective cohort study embedded in the ISARIC-WHO COVID-19 Clinical Characterisation Protocol. Patients with laboratory-confirmed SARS-CoV-2 infection who required hospital admission were recruited prospectively. Patients treated with HFNC, NIV, or IMV within the first 24 h of hospital admission were included in this study. Descriptive statistics, random forest, and logistic regression analyses were used to describe clinical characteristics and compare clinical outcomes among patients treated with the different types of advanced respiratory support.ResultsA total of 66,565 patients were included in this study. Overall, 82.6% of patients were treated in HIC, and 40.6% were admitted to the hospital during the first pandemic wave. During the first 24 h after hospital admission, patients in HICs were more frequently treated with HFNC (48.0%), followed by NIV (38.6%) and IMV (13.4%). In contrast, patients admitted in lower- and middle-income countries (LMICs) were less frequently treated with HFNC (16.1%) and the majority received IMV (59.1%). The failure rate of non-invasive respiratory support (i.e. HFNC or NIV) was 15.5%, of which 71.2% were from HIC and 28.8% from LMIC. The variables most strongly associated with non-invasive ventilation failure, defined as progression to IMV, were high leukocyte counts at hospital admission (OR [95%CI]; 5.86 [4.83–7.10]), treatment in an LMIC (OR [95%CI]; 2.04 [1.97–2.11]), and tac
AU  - Reyes,LF
AU  - Murthy,S
AU  - Garcia-Gallo,E
AU  - Merson,L
AU  - Ibanez-Prada,ED
AU  - Rello,J
AU  - Fuentes,Y
AU  - Martin-Loeches,I
AU  - Bozza,F
AU  - Duque,S
AU  - Taccone,FS
AU  - Fowler,RA
AU  - Kartsonaki,C
AU  - Goncalves,BP
AU  - Citarella,BW
AU  - Aryal,D
AU  - Burhan,E
AU  - Cummings,MJ
AU  - Delmas,C
AU  - Diaz,R
AU  - Figueiredo-Mello,C
AU  - Hashmi,M
AU  - Panda,PK
AU  - Jimenez,MP
AU  - Rincon,DFB
AU  - Thomson,D
AU  - Nichol,A
AU  - Marshall,JC
AU  - Olliaro,PL
DO  - 10.1186/s13054-022-04155-1
EP  - 16
PY  - 2022///
SN  - 1364-8535
SP  - 1
TI  - Respiratory support in patients with severe COVID-19 in the International Severe Acute Respiratory and Emerging Infection (ISARIC) COVID-19 study: a prospective, multinational, observational study
T2  - Critical Care (UK)
UR  - http://dx.doi.org/10.1186/s13054-022-04155-1
UR  - https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000853343900001&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=1ba7043ffcc86c417c072aa74d649202
UR  - https://ccforum.biomedcentral.com/articles/10.1186/s13054-022-04155-1
UR  - http://hdl.handle.net/10044/1/105233
VL  - 26
ER  -

Download

DR. DANIEL MUNBLIT

Contact

Location

Summary

Citation

BibTex format

RIS format (EndNote, RefMan)